Nov 27, 2017 | By Tess

Hangzhou Regenovo Biotechnology Co., Ltd. has unveiled China’s first ever high-throughput 3D bioprinter for mass producing human tissues. The 3D bioprinter, named the Bio-architect X, was introduced by the biotech company at the "Development of Functional Materials and High-throughput Integrated Biological 3D Printing Technology" event in Hangzhou’s Economic and Technological Development Zone.

The company behind the new 3D bioprinter, Regenovo, was founded by a group of medical professionals and university professors who had the shared goal of developing biomedical 3D printing technologies for the advancement of healthcare solutions.

As the recent presentation of its Bio-architect X bioprinter demonstrates, Regenovo has succeeded in bringing to market an additive manufacturing system for high-throughput bioprinting.

The 3D bioprinter, which integrates an innovative Micro-computed tomography system (MCT), is reportedly capable of printing all types of tissues and organs. As a company rep stated at the unveiling, “In principal, this biological 3D printer can print all the tissues and organs.”

The Bio-architect X system is said to have important applications in China’s medical field, perhaps most notably in the realm of drug testing and screening processes. The company says it hopes its 3D bioprinter will encourage the development and production of new drugs within the Asian country.

At the “Development of Functional Materials and High-throughput Integrated Biological 3D Printing Technology” event, Regenovo demonstrated its 3D bioprinter by manufacturing a piece of nasal cartilage.

For the demo, Regenovo staff turned on the printer’s computer, selected a 3D model of a nasal cartilage structure and simply pressed the start button. From there, the 3D bioprinter burst into action, as its nozzle began depositing a hydrogel material embedded with human cells into the desired shape. In under an hour, visitors were able to get a glimpse of the 3D printed nasal cartilage.

The hydrogel materials being printed are also developed by Regenovo, which specializes in developing bioinks for human liver cells, blood vessels, etc. According to the company, its printed cell survival rate is up to 90% and it has successfully kept cells alive for up to four months.

The 3D bioprinter itself is compatible with a range of different “printing principles,” which enable it to manufacture large quantities of medical products, explained Professor Xu Ming En, the chairman of Regenovo and a chief scientist for the bioprinter’s development.

The MCT technology the bioprinter integrates is also worth mentioning. Developed by Wang Ling, an associate professor at the Hangzhou Dianzi University, MCT provides a more advanced alternative to existing imaging systems such as CT scanning, which is limited by the volume of objects, the depth of signal penetration, and causes radiation damage.

MCT, however, is based on micro-chromatographic technology, which is capable of high resolution imaging with no depth limitation, and can be captured without physical contact or risk of cell damage. It therefore is suited for providing real-time feedback for the 3D prints in progress, and allows users to adjust printing parameters to control the bioprinter output.

The recently unveiled Bio-architect X for high-throughput printing is preceded by Regenovo’s Bio-Architect–Lite, Bio-Architect–Pro, and Bio-Architect–WS systems.

 

 

Posted in 3D Printer

 

 

Maybe you also like:


   






Leave a comment:

Your Name:

 


Subscribe us to

3ders.org Feeds 3ders.org twitter 3ders.org facebook   

About 3Ders.org

3Ders.org provides the latest news about 3D printing technology and 3D printers. We are now six years old and have around 1.5 million unique visitors per month.

News Archive